Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation

Table 1

Patient and donor characteristics.

Characteristics
Median age (range), years	26 (2–58)
Male sex, n (%)	231 (58.6%)
Diagnosis
AML, n (%)	160 (40.6%)
ALL, n (%)	133 (33.8%)
CML, n (%)	22 (5.6%)
MDS, n (%)	41 (10.4%)
Others, n (%)	38 (9.6%)
Disease status, SR (%)	301 (76.4%)
Conditioning regimen
MA, n (%)	394 (100%)
Number of HLA-A, B, DR mismatched, n (%)
0	3 (0.8%)
1	22 (5.6%)
2	87 (22.1%)
3	282 (71.6%)
Donor-recipient sex match, n (%)
Male-male	149 (37.8%)
Male-female	102 (25.9%)
Female-male	84 (21.3%)
Female-female	59 (15%)
Donor-recipient relationship, n (%)
Father-child	150 (38.1%)
Mother-child	57 (14.5%)
Sibling-sibling	117 (29.%)
Child-parent	58 (14.7%)
Others	12 (3.0%)
ABO matched, n (%)
Matched	224 (56.9%)
Major mismatched	74 (18.8%)
Minor mismatched	22 (5.6%)
Bidirect mismatched	74 (18.8%)
Cell compositions in allografts, median (range)
Infused nuclear cells, 10^8/kg	8.23 (1.78–23.69)
Infused CD34+ cells, 10^6/kg	2.61 (0.39–16.82)
Infused lymphocytes, 10^8/kg	2.93 (0.16–9.49)
Infused CD3+ cells, 10^8/kg	2.0 (0.1–5.93)
Infused CD4+ cells, 10^8/kg	1.1 (0.15–3.94)
Infused CD8+ cells, 10^8/kg	0.69 (0.05–2.47)
Infused CD14+ cells, 10^8/kg	1.48 (0.19–6.13)
aGVHD
Grade 0-I aGVHD	259 (65.7%)
Grade II–IV aGVHD	135 (34.3%)
cGVHD
No cGVHD	266 (67.5%)
cGVHD	128 (32.5%)